Thessaloniki

• A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in P … Recruiting
  2024-515172-12-00 4 2025-12-23 Epidermolysis Bullosa
• A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab … Recruiting
  2024-519494-19-00 5 2025-12-22 Nutritional and metabolic diseases
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear … Recruiting
  2023-505661-89-00 4 2025-12-19 Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
• A study to find how well budoprutug (TNT119) works and how safe it is in participants with immune thrombocytopenia Recruiting
  2024-519745-30-01 9 2025-12-19 Immune Thrombocytopenia (ITP)
• An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489 Recruiting
  2025-521155-23-00 4 2025-12-19 Pulmonary Arterial Hypertension
• A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia Recruiting
  2025-521692-31-00 5 2025-12-19 Chronic Primary Immune Thrombocytopenia
• A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and ch … Recruiting
  2025-523009-14-00 4 2025-12-16 Bronchiectasis with chronic pseudomonas aeruginosa colonization
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous … Recruiting
  2025-520730-28-00 4 2025-12-08 Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A phase 3b study of depemokimab on airway structure and function in patients with type 2 asthma utilizing quantitative high-resolution CT an … Recruiting
  2024-519976-19-00 5 2025-11-26 Asthma with type 2 inflammation characterized by an eosinophilic pheno
• A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus Recruiting
  2024-520385-57-01 3 2025-11-26 Systemic Lupus Erythematosus
• A clinical study of MK-1084 in people with advanced solid tumors (MK 1084-014) Recruiting
  2025-521737-91-00 4 2025-11-25 Neoplasm malignant with KRAS G12C mutation
• A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting
  2025-521920-31-00 4 2025-11-21 Graves’ Disease
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520746-30-00 5 2025-11-18 Mild to moderate Alzheimer’s Disease
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• A Study to Evaluate the Efficacy and Safety of Mezagitamab Subcutaneous Injection Compared With Placebo in Adults With Chronic Immune Thromb … Recruiting
  2024-514401-54-00 5 2025-11-13 Chronic Primary Immune Thrombocytopenia
• Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting
  2024-515979-35-00 5 2025-11-13 Generalized Myasthenia Gravis
• A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting
  2024-517553-26-00 5 2025-11-12 Advanced ALK-positive non-small cell lung cancer (NSCLC)
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting
  2024-519345-30-00 5 2025-11-12 IgA nephropathy
• A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting
  2024-520190-12-00 5 2025-11-10 Breast Cancer: triple negative breast cancer (TNBC) and hormone recept

Showing 145–168 of 655 trials